ZA200007299B - Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol. - Google Patents

Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.

Info

Publication number
ZA200007299B
ZA200007299B ZA200007299A ZA200007299A ZA200007299B ZA 200007299 B ZA200007299 B ZA 200007299B ZA 200007299 A ZA200007299 A ZA 200007299A ZA 200007299 A ZA200007299 A ZA 200007299A ZA 200007299 B ZA200007299 B ZA 200007299B
Authority
ZA
South Africa
Prior art keywords
androst
ene
diol
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
ZA200007299A
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of ZA200007299B publication Critical patent/ZA200007299B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200007299A 1998-06-11 2000-12-08 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol. ZA200007299B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9628698A 1998-06-11 1998-06-11

Publications (1)

Publication Number Publication Date
ZA200007299B true ZA200007299B (en) 2002-04-24

Family

ID=22256669

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200007299A ZA200007299B (en) 1998-06-11 2000-12-08 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.

Country Status (23)

Country Link
US (12) US6432940B1 (ko)
EP (2) EP1083904A2 (ko)
JP (1) JP2002517432A (ko)
KR (3) KR20060098400A (ko)
CN (3) CN1879630A (ko)
AR (1) AR018660A1 (ko)
AU (1) AU4127499A (ko)
BR (1) BR9911115A (ko)
CA (1) CA2334702C (ko)
HK (2) HK1078004A1 (ko)
HU (1) HUP0102483A3 (ko)
ID (1) ID27922A (ko)
IL (2) IL140225A0 (ko)
MX (1) MXPA00012304A (ko)
MY (1) MY131522A (ko)
NO (1) NO20006286L (ko)
NZ (1) NZ536787A (ko)
PL (1) PL345955A1 (ko)
RU (1) RU2221569C2 (ko)
TR (2) TR200102867T2 (ko)
TW (2) TWI263499B (ko)
WO (1) WO1999063973A2 (ko)
ZA (1) ZA200007299B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
PE20010404A1 (es) 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
FR2825277B1 (fr) * 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
WO2003070253A1 (en) * 2002-02-21 2003-08-28 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women
WO2003090754A1 (en) * 2002-04-23 2003-11-06 Sahltech I Göteborg AB Use of dhea for treatment of female hypopituitarism
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
AU2003278744B2 (en) * 2002-08-28 2010-07-29 Harbor Biosciences, Inc. Therapeutic treatment methods
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP1761270A1 (en) * 2004-06-23 2007-03-14 Merck & Co., Inc. Estrogen receptor modulators
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
JP2008517952A (ja) * 2004-11-01 2008-05-29 アンドルシェルシュ・インコーポレイテッド 皮膚老化となる可能性を低下させるための、または皮膚老化を処置するためのアンドロゲンの使用
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
EP2053055A1 (de) * 2007-10-24 2009-04-29 Bayer Schering Pharma Aktiengesellschaft 11.beta.-Fluoro-3-acetoxyestra-3,5-dien-17-on und Verfahren zu seiner Herstellung
JP2010109894A (ja) * 2008-10-31 2010-05-13 Fujitsu Ltd 弾性波フィルタ、デュープレクサ、通信モジュール、および通信装置
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2802761C (en) 2010-06-16 2017-01-03 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US20130178747A1 (en) * 2012-01-10 2013-07-11 Peter J. Muran Breast cancer precursor evaluation system and proactive breast wellness program
CN105037532B (zh) * 2015-07-27 2018-02-09 苏州博源医疗科技有限公司 17‑酮类固醇免疫原、抗体和检测试剂及制备方法
CN111830169B (zh) * 2020-07-24 2022-07-12 中山大学 多囊卵巢综合征诊断的化合物及应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US424954A (en) * 1890-04-08 Table-knife
US279982A (en) * 1883-06-26 Thomas beid
US816689A (en) * 1904-07-07 1906-04-03 Charles M Stevenson Merry-go-round.
CH203260A (de) 1936-11-24 1939-02-28 Dreiding Boris Mittel zur örtlichen Erzeugung von Wärme.
US2185187A (en) * 1938-05-23 1940-01-02 Vlieg Gerard A De Rotary cutter
FR672M (ko) * 1960-08-31 1961-07-17
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4040401A (en) 1974-11-05 1977-08-09 Ethyl Corporation Spark vacuum advance control
US4064654A (en) 1975-03-20 1977-12-27 H. G. Olson & Co., Inc. Sealed closures with weather stripping
JPS53144014A (en) 1977-05-20 1978-12-15 Masaya Koyama Automatic sprayer
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4634694A (en) 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5887216A (en) * 1997-03-19 1999-03-23 Ricoh Company, Ltd. Method and system to diagnos a business office device based on operating parameters set by a user
US5686465A (en) * 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
IL92496A0 (en) 1988-12-01 1990-08-31 Schering Corp Compositions for transdermal delivery of estradiol
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
ATE193447T1 (de) * 1992-02-24 2000-06-15 Univ East Carolina Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
NZ512334A (en) 1993-01-19 2005-05-27 Endorech Inc Therapeutic methods and delivery systems utilizing sex steroid precursors
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5828688A (en) * 1995-10-26 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for linewidth reduction in distributed feedback or distributed bragg reflector semiconductor lasers using vertical emission
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
IT1292129B1 (it) * 1997-06-11 1999-01-25 Sunnimex Ltd Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
AU5957500A (en) * 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002092102A2 (en) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins

Also Published As

Publication number Publication date
US20020187966A1 (en) 2002-12-12
IL175723A0 (en) 2006-09-05
MY131522A (en) 2007-08-30
EP1083904A2 (en) 2001-03-21
HK1078004A1 (en) 2006-03-03
CA2334702A1 (en) 1999-12-16
US6884795B2 (en) 2005-04-26
US20020187965A1 (en) 2002-12-12
CN1311682A (zh) 2001-09-05
TR200100063T2 (tr) 2001-05-21
KR20010052764A (ko) 2001-06-25
MXPA00012304A (es) 2003-05-15
IL140225A0 (en) 2002-02-10
US20020187973A1 (en) 2002-12-12
HK1037329A1 (en) 2002-02-08
KR100679735B1 (ko) 2007-02-07
NZ536787A (en) 2006-03-31
NO20006286D0 (no) 2000-12-11
JP2002517432A (ja) 2002-06-18
TWI263499B (en) 2006-10-11
US20020187964A1 (en) 2002-12-12
CN1243550C (zh) 2006-03-01
US20020187968A1 (en) 2002-12-12
EP1731157A2 (en) 2006-12-13
PL345955A1 (en) 2002-01-14
NO20006286L (no) 2001-01-31
KR20060098400A (ko) 2006-09-18
AU4127499A (en) 1999-12-30
US20020187962A1 (en) 2002-12-12
US20080161277A1 (en) 2008-07-03
HUP0102483A3 (en) 2002-11-28
KR20060098399A (ko) 2006-09-18
TR200102867T2 (ko) 2002-06-21
US20020187969A1 (en) 2002-12-12
US20020187963A1 (en) 2002-12-12
TW200630101A (en) 2006-09-01
US6432940B1 (en) 2002-08-13
BR9911115A (pt) 2001-12-04
CN100377711C (zh) 2008-04-02
US6964955B2 (en) 2005-11-15
HUP0102483A2 (hu) 2001-11-28
TWI283579B (en) 2007-07-11
AR018660A1 (es) 2001-11-28
WO1999063973A2 (en) 1999-12-16
ID27922A (id) 2001-05-03
US20020187970A1 (en) 2002-12-12
WO1999063973A3 (en) 2000-11-02
CN1626095A (zh) 2005-06-15
CA2334702C (en) 2005-10-18
RU2221569C2 (ru) 2004-01-20
US20020187967A1 (en) 2002-12-12
CN1879630A (zh) 2006-12-20
EP1731157A3 (en) 2009-07-15
US6995150B2 (en) 2006-02-07

Similar Documents

Publication Publication Date Title
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
HUP0103341A3 (en) Azetidine derivatives, preparation and pharmaceutical compositions thereof
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
IL152448A0 (en) 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
HK1045650A1 (en) Pharmaceutical composition.
HK1047584A1 (en) Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process.
HK1038884A1 (en) Medicinal compositions.
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0203505A3 (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, and pharmaceutical compositions containing said compounds
PL343512A1 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
ZA200104280B (en) Pharmaceutical combination preparations.
HUP0102515A3 (en) Cyclopeptides, process for their preparation, pharmaceutical compositions comprising thereof and their use
ZA200005510B (en) Pharmaceutical composition.
ZA200110150B (en) Streptogramin derivatives, preparation and compositions containing them.
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
ZA991232B (en) New compound and pharmaceutical compositions thereof.
ZA99890B (en) Pharmaceutical compositions.
NZ329271A (en) 4-benzyl-piperidin-4-ol derivatives, preparation and pharmaceutical compositions thereof
ZA99168B (en) Pharmaceutical formulations and processes for their preparation.